Compare Deckers Outdoor Corp (DECK) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Gilead Sciences, Inc. — how do they compare? Deckers Outdoor Corp trades at $106.98 (market cap $14.97B), while Gilead Sciences, Inc. trades at $129.81 (market cap $163.14B). The key difference: Gilead Sciences, Inc. is far larger — about 10.9× Deckers Outdoor Corp's market cap, and Gilead Sciences, Inc. pays a 2.5% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals.
| DECK | GILD | |
|---|---|---|
Market Cap | $14.97B | $163.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $123.91 | $155.80 |
52-Week Low | $79.54 | $108.22 |
Enterprise Value | $13.44B | $177.67B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Gilead Sciences (GILD) trades at $131.40, up 1.21% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA approvals for Trodelvy in metastatic triple-negative breast cancer and ongoing Ebola antiviral trials highlight pipeline strength. Analyst consensus remains strongly positive with a $152.83 price target.
GILD presents a compelling investment case with strong profitability, expanding oncology portfolio, and 67% analyst buy ratings. Key risks include patent expirations on HIV drugs and volatile cash flow trends. The stock offers 16% upside to consensus target with dividend support, though investors should monitor pipeline execution and generic competition timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
